A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis

被引：0

作者：

Ehst, B. ^{[1
]}

Silverberg, J. ^{[2
]}

Lizzul, P. ^{[3
]}

Luu, K. ^{[3
]}

Papacharalambous, J. ^{[3
]}

Raina, P. ^{[3
]}

Randazzo, B. ^{[3
]}

Sibley, C. ^{[3
]}

Guttman-Yassky, E. ^{[4
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[3] AnaptysBio, San Diego, CA USA

[4] Icahn Sch Med Mt Sinai, New York, NY USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：S347 / S347

页数：1

共 50 条

[1] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao, Yan
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Jia, Yingmin
Zhao, Guoqing
Yan, Jinchun
Chen, Bo
[J]. CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
[2] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao Yan
Zhang Jianzhong
Yang Bin
Li Jingyi
Ding Yangfeng
Wu Liming
Zhang Litao
Wang Jinyan
Zhu Xiaohong
Zhang Furen
Tao Xiaohua
Li Yumei
Zhang Chunlei
Li Linfeng
Lu Jianyun
Diao Qingchun
Lu Qianjin
Man Xiaoyong
Li Fuqiu
Xia Xiujuan
Cheng Hao
Jia Yingmin
Zhao Guoqing
Yan Jinchun
Chen Bo
[J]. 中华医学杂志(英文版), 2024, 137 (02)
[3] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
Zhao, Y.
Wu, L.
Lu, Q.
Gao, X.
Zhu, X.
Yao, X.
Li, L.
Li, W.
Ding, Y.
Song, Z.
Liu, L.
Dang, N.
Zhang, C.
Liu, X.
Gu, J.
Wang, J.
Geng, S.
Liu, Q.
Guo, Y.
Dong, L.
Su, H.
Bai, L.
O'Malley, J. T.
Luo, J.
Laws, E.
Mannent, L.
Ruddy, M.
Amin, N.
Bansal, A.
Ota, T.
Wang, M.
Zhang, J.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
[4] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Tyring, Stephen K. K.
Rich, Phoebe
Tada, Yayoi
Beeck, Stefan
Messina, Izabella
Liu, Jie
Huang, Xiaohong
Shumack, Stephen
[J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
[5] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
[J]. Dermatology and Therapy, 2023, 13 : 595 - 608
[6] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Torrelo, A.
Rewerska, B.
Paller, Amy
Prakash, A.
Zhu, D.
Pontes, M.
Wu, Wen-Shuo
Eichenfield, Lawrence F.
Boecker, Ulrike
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
[7] EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Zhao, Yan
Chen, Bo
Yan, Jinchun
Zhao, Guoqing
Jia, Yingmin
[J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 20 - 20
[8] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
Guttman-Yassky, Emma
Esfandiari, Ehsanollah
Mano, Hirotaka
Arai, Takahiro
Kabashima, Kenji
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[9] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Guttman-Yassky, Emma
Simpson, Eric L.
Reich, Kristian
Kabashima, Kenji
Igawa, Ken
Suzuki, Tetsuya
Mano, Hirotaka
Matsui, Takeshi
Esfandiari, Ehsanollah
Furue, Masutaka
[J]. LANCET, 2023, 401 (10372): : 204 - 214
[10] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
Gooderham, Melinda
Lynde, Charles
Alam, Maryam Shayesteh
Sadick, Neil
Rohan, Craig A.
Werschler, William Philip
Hebert, Adelaide A.
Laquer, Vivian T.
Sauder, Maxwell
Del Rosso, James Q.
Rodgers, Timothy
Tan, Ricardo
Schleicher, Stephen
Murrell, Dedee F.
Fernandez-Penas, Pablo
Reich, Adam
Gkalpakiotis, Spyridon
Ruiz, Juan Ruano
Wollenberg, Andreas
Szepietowski, Jacek C.
Sticherling, Michael
Weyergraf, Ansgar J.
Hadzavdic, Suzana Ljubojevic
Baran, Wojciech
Vilchez, Trinidad Montero
Eniko, Telegdy
Sebastian, Michael
Chaudhry, Sohail
Lee, Zachary
Yu, Danni
Liu, Yi
Waltz, Wang
Gilbert, Jenny
Elko-Simms, Lucinda M.
Fanton, Christie
Jue, Charleen
Tagliaferri, Mary
Zalevsky, Jonathan
Rosmarin, David
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 105 - 107

← 1 2 3 4 5 →